Peptide-Based Drug Discovery
267,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Gebundenes Buch

This book provides a complete view of what it takes to develop peptide-based medicine from a chemistry perspective and insights into the future of peptide drugs.

Andere Kunden interessierten sich auch für
Produktbeschreibung
This book provides a complete view of what it takes to develop peptide-based medicine from a chemistry perspective and insights into the future of peptide drugs.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Ved Srivastava is Vice President of Chemistry and co-founder at Phoundry Pharmaceuticals, and prior to that he was head of Peptide Chemistry at GlaxoSmithKline and Vice President of research and production at New England Peptide. He spent several years with Amylin Pharmaceuticals where he focused on discovery and development of novel peptide hormones for diabetes, obesity and neuropsychiatric therapies. He has significantly contributed in the development of ByettaTM, SymlinTM and BydeureonTM for the treatment of diabetes. He also directed the research chemistry team of Psylin Neurosciences, Inc., a biotech company formed as a joint venture between Amylin Pharmaceuticals, Inc. and PshychoGenics, Inc. Ved has over 25 years of experience with expertise in drug discovery in the area metabolic diseases and inflammation with major emphasis in peptide medicinal chemistry and peptide delivery. He earned a Ph.D.in organic chemistry from the University of Lucknow, India and had subsequent postdoctoral appointments at the University of Georgia and the University of Colorado Medical School. Ved is energetically involved in the governance of the American Peptide Society.